Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Business

Walgreens to invest over $5.5 billion in health services push

2021 10 14T135530Z 3 LYNXMPEH9D0MZ RTROPTP 4 USA OPIOIDS LITIGATION - Global Banking | Finance

By Leroy Leo and Dania Nadeem

(Reuters) -Walgreens Boots Alliance Inc said on Thursday it would take majority stakes in two smaller health care providers for about $5.5 billion, as the second largest U.S. pharmacy chain shifts focus beyond its drugstores.

Shares in Walgreens rose nearly 7% to $50.44 in afternoon trading after it reported fourth-quarter results that beat estimates, helped by easing pandemic-related restrictions and COVID-19 vaccine administrations at its stores.

The company said it would make a $5.2 billion investment in VillageMD, raising its stake https://reut.rs/3AGlbg2 in the primary care provider to 63%. It will also invest $330 million in post-acute and home care provider CareCentrix to take a 55% stake.

Walgreens, which has more than 9,000 drugstores across the country, said these investments will support its new business unit that will provide pharmacy and primary care services in-store, at home, in the doctor’s office and via mobile app.

Rosalind Brewer, who took over as CEO earlier this year, said the deals will help Walgreens manage rising costs in high-risk patients. “These are the same patients who frequently visit our stores and meet with our pharmacists,” Brewer added.

Walgreens said it expects adjusted earnings growth, at constant currency rates, to be flat for fiscal year 2022.

The company aims to open at least 600 physician-led primary care clinics in more than 30 U.S. markets by 2025 and 1,000 clinics by 2027.

Walgreens and VillageMD have 52 primary care practice locations with pharmacy and doctor offices together, and will have more than 80 such locations by the end of this calendar year, the company said.

Same-store sales at its U.S. pharmacies rose 8.8% in the fourth quarter, which included a 485 basis point boost from COVID-19 vaccinations, the company said.

Excluding items, Walgreens earned $1.17 per share, compared with Refinitiv IBES estimates of $1.02 per share.

(Reporting by Dania Nadeem and Leroy Leo in Bengaluru; Editing by Vinay Dwivedi)

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review │ Banking │ Finance │ Technology. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post